## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### SCHEDULE 13G\*

(Rule 13d-102)

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. \_\_)\*

Aclaris Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value \$0.00001 per share (the "Shares")
(Title of Class of Securities)
00461U105
(CUSIP Number)
August 25, 2023
(Date of Event Which Requires Filing of the Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:  □ Rule 13d-1(b)  ⊠ Rule 13d-1(c) □ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	NAME OF REPORTING PERSONS						
	Citadel Advis	Citadel Advisors LLC					
2.	CHECK THE	(a)					
3.	SEC USE ONI	LY					
4.	CITIZENSHIP	OR PLACE	OF ORGANIZATION				
	Delaware						
	•	5.	SOLE VOTING POWER				
NII IN AE	PER OF		0				
BENEFI	RES CIALLY	6.	SHARED VOTING POWER  3,317,794 Shares				
EA REPO PER	OWNED BY EACH REPORTING PERSON		SOLE DISPOSITIVE POWER  0				
WI	TH	8.	SHARED DISPOSITIVE POWER				
			See Row 6 above				
9.	AGGREGATE	AMOUNT 1	BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	See Row 6 abo			_			
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	4.7% <sup>1</sup>						
12.	TYPE OF REPORTING PERSON						
	IA: OO: HC						

 $<sup>\</sup>frac{1}{2}$  The percentages reported in this Schedule 13G are based upon 70,794,642 Shares outstanding as of July 31, 2023 (according to the issuer's Form 10-Q as filed with the Securities and Exchange Commission on August 7, 2023). Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on September 5, 2023.

CUSIP No. 00461U105	
---------------------	--

Page 3 of 13 Pages

1.	NAME OF REPORTING PERSONS				
	Citadel Advis	ors Holdings	LP		
2.	CHECK THE	(a)			
3.	SEC USE ONLY				
4.	CITIZENSHII	OR PLACE	OF ORGANIZATION		
	Delaware				
	1	5.	SOLE VOTING POWER		
NILINAE	ED OF		0		
SHA	ER OF RES	6.	SHARED VOTING POWER		
	CIALLY ED BY		3,317,794 Shares		
EA REPO	CH RTING	7.	SOLE DISPOSITIVE POWER		
PERSON WITH			0		
***	111	8.	SHARED DISPOSITIVE POWER		
			See Row 6 above		
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	See Row 6 ab	ove			
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	4.7%				
12.	TYPE OF REI	PORTING PE	RSON		
	PN; HC				

1.	NAME OF REPORTING PERSONS					
	Citadel GP LLC					
2.	CHECK THE AI	(a)				
3.	SEC USE ONLY					
4.	CITIZENSHIP C	R PLACE	OF ORGANIZATION			
	Delaware					
		5.	SOLE VOTING POWER			
NILIME	BER OF		0			
SHA BENEF	ARES ICIALLY ED BY	6.	SHARED VOTING POWER  3,317,794 Shares			
EA REPO PER	CH RTING SON	7.	SOLE DISPOSITIVE POWER  0			
W	TH	8.	SHARED DISPOSITIVE POWER			
			See Row 6 above			
9.			BENEFICIALLY OWNED BY EACH REPORTING PERSON			
10		See Row 6 above				
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  0					
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	4.7%					
12.	TYPE OF REPO	RTING PE	ERSON			
	00; HC					

CUSIP No. 00461U105	13G	Page 5 of 13 Pages
---------------------	-----	--------------------

1.	NAME OF REF	PORTING F	PERSONS				
	Citadel Securit	ties LLC					
2.	CHECK THE A	(a)					
3.	SEC USE ONL	SEC USE ONLY					
4.	CITIZENSHIP	OR PLACE	E OF ORGANIZATION				
	Delaware	Delaware Control of the Control of t					
		5.	SOLE VOTING POWER				
NILINA	DED OF		0				
SH	BER OF ARES	6.	SHARED VOTING POWER				
	TICIALLY IED BY		268,970 Shares				
	ACH ORTING	7.	SOLE DISPOSITIVE POWER				
	RSON TTH		0				
		8.	SHARED DISPOSITIVE POWER				
			See Row 6 above				
9.	AGGREGATE .	AMOUNT	BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	See Row 6 above						
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	DED CENTE OF	CI ACC DE	DRECENTED BY AMOUNT IN DOMEON				
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
12		0.4%					
12.	TYPE OF REPORTING PERSON						
	BD: OO						

CUSIP No. 00461U105	
---------------------	--

13G

Page 6 of 13 Pages

1.	NAME OF RE	NAME OF REPORTING PERSONS				
	Citadel Secur	ities Group l	LP			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP					
3.	SEC USE ONLY					
4.	CITIZENSHII	P OR PLACE	OF ORGANIZATION			
	Delaware					
		5.	SOLE VOTING POWER			
) III (F	ED OF		0			
	RES	6.	SHARED VOTING POWER			
BENEFI OWNI	CIALLY ED BY		268,970 Shares			
EA REPO		7.	SOLE DISPOSITIVE POWER			
PERSON WITH			0			
***	WITH		SHARED DISPOSITIVE POWER			
			See Row 6 above			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	See Row 6 ab	ove				
10.	CHECK IF TH	HE AGGREG	ATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
				Ц		
11.	PERCENT OF	F CLASS RE	PRESENTED BY AMOUNT IN ROW (9)			
	0.4%					
12.	TYPE OF RE	PORTING PE	ERSON			
	PN; HC					

13G

Page 7 of 13 Pages

1.	NAME OF REPORTING PERSONS				
	Citadel Securitie	es GP LL	C		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
3.	SEC USE ONLY				
4.	CITIZENSHIP O	R PLACE	OF ORGANIZATION		
	Delaware				
		5.	SOLE VOTING POWER		
NII IN AID	VED OF		0		
SHA	ER OF RES	6.	SHARED VOTING POWER		
	CIALLY ED BY		268,970 Shares		
	CH RTING	7.	SOLE DISPOSITIVE POWER		
	SON TH		0		
,,,,		8.	SHARED DISPOSITIVE POWER		
			See Row 6 above		
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	See Row 6 above	2			
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11.	PERCENT OF C	LASS RE	PRESENTED BY AMOUNT IN ROW (9)		
	0.4%				
12.	TYPE OF REPORTING PERSON				
	00; HC				
	00,110				

13G

Page 8 of 13 Pages

1.	NAME OF REPORTING PERSONS			
	Kenneth Griffin			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLACE OF ORGANIZATION			
U.S. Citizen				
		5.	SOLE VOTING POWER	
) III 6	ALD OF		0	
SHA	ER OF RES	6.	SHARED VOTING POWER	
	CIALLY ED BY		3,586,764 Shares	
	CH RTING	7.	SOLE DISPOSITIVE POWER	
PERSON WITH			0	
		8.	SHARED DISPOSITIVE POWER	
			See Row 6 above	
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	See Row 6 above			
10.	10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
5.1%				
12. TYPE OF REPORTING PERSON				
	IN; HC			

#### Item 1(a). Name of Issuer:

Aclaris Therapeutics, Inc.

#### Item 1(b). Address of Issuer's Principal Executive Offices:

640 Lee Road, Suite 200, Wayne, PA 19087

#### Item 2(a). Name of Person Filing:

This Schedule 13G is being jointly filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the "Reporting Persons") with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company ("CM"), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares.

Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.

The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

#### Item 2(b). Address or Principal Business Office or, if none, Residence:

The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.

#### Item 2(c). Citizenship:

Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.

#### Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.00001 per share

#### Item 2(e). CUSIP Number:

00461U105

CUSIP No. 00461U105	13G	Page 10 of 13 Pages	

tem 3.	If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:				
	(a)		Broker or dealer registered under Section 15 of the Act (15 U.S.C. 780);		
	(b)		Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);		
	(c)		Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);		
	(d)		Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);		
	(e)		An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);		
	(f)		An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);		
	(g)		A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);		
	(h)		A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);		
	(i)		A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the		
			Investment Company Act (15 U.S.C. 80a-3);		
	(j)		A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);		
	(k)		Group, in accordance with § 240.13d-1(b)(1)(ii)(K).		
	If filing	g as a non-	U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:		
tem 4.	Owner	rship:			
	A.	Citade	l Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC		
		(a)	Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficiall own 3,317,794 Shares.		
		(b)	The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC mabe deemed to beneficially own constitutes 4.7% of the Shares outstanding.		
		(c)	Number of Shares as to which such person has:		
			(i) sole power to vote or to direct the vote: 0		
			(ii) shared power to vote or to direct the vote: 3,317,794		

sole power to dispose or to direct the disposition of:  $\,0\,$ 

shared power to dispose or to direct the disposition of: 3,317,794

(iii)

(iv)

- B. Citadel Securities LLC
  - (a) Citadel Securities LLC may be deemed to beneficially own 268,970 Shares.
  - (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.4% of the Shares outstanding.
  - (c) Number of Shares as to which such person has:
    - (i) sole power to vote or to direct the vote: 0
    - (ii) shared power to vote or to direct the vote: 268,970
    - (iii) sole power to dispose or to direct the disposition of: 0
    - (iv) shared power to dispose or to direct the disposition of: 268,970
- C. Citadel Securities Group LP and Citadel Securities GP LLC
  - (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 268,970 Shares.
  - (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.4% of the Shares outstanding.
  - (c) Number of Shares as to which such person has:
    - (i) sole power to vote or to direct the vote: 0
    - (ii) shared power to vote or to direct the vote: 268,970
    - (iii) sole power to dispose or to direct the disposition of: 0
    - (iv) shared power to dispose or to direct the disposition of: 268,970

#### D. Kenneth Griffin

- (a) Mr. Griffin may be deemed to beneficially own 3,586,764 Shares.
- (b) The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 5.1% of the Shares outstanding.
- (c) Number of Shares as to which such person has:
  - (i) sole power to vote or to direct the vote: 0
  - (ii) shared power to vote or to direct the vote: 3,586,764
  - (iii) sole power to dispose or to direct the disposition of: 0
  - (iv) shared power to dispose or to direct the disposition of: 3,586,764

#### Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following.  $\Box$ 

#### Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

Not Applicable

### Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

Not Applicable

#### Item 8. Identification and Classification of Members of the Group:

Not Applicable

#### Item 9. Notice of Dissolution of Group:

Not Applicable

#### Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 00461U105	13G	Page 13 of 13 Pages
---------------------	-----	---------------------

#### **SIGNATURE**

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

CITADEL ADVISODELLO

Dated September 5, 2023.

CITADEL SECUDITIES LLC

CHADEL SECORITIES LLC			CHADEL ADVISORS LLC		
By:	/s/ Guy Miller Guy Miller, Authorized Signatory	By:	/s/ Noah Goldberg Noah Goldberg, Authorized Signatory		
CITADEL SECURITIES GROUP LP			CITADEL ADVISORS HOLDINGS LP		
By:	/s/ Guy Miller Guy Miller, Authorized Signatory	By:	/s/ Noah Goldberg Noah Goldberg, Authorized Signatory		
CITADEL SECURITIES GP LLC			CITADEL GP LLC		
Ву:	/s/ Guy Miller Guy Miller, Authorized Signatory	By:	/s/ Noah Goldberg Noah Goldberg, Authorized Signatory		
		KENN	NETH GRIFFIN		
		By:	/s/ Noah Goldberg Noah Goldberg, attorney-in-fact*		

<sup>\*</sup> Noah Goldberg is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Zentalis Pharmaceuticals Inc. on April 9, 2020.

#### **JOINT FILING AGREEMENT**

The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Aclaris Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned.

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

Dated September 5, 2023.

CITADEL SECURITIES LLC		CITADEL ADVISORS LLC			
By:	/s/ Guy Miller	By:	/s/ Noah Goldberg		
	Guy Miller, Authorized Signatory		Noah Goldberg, Authorized Signatory		
CITADEL SECURITIES GROUP LP		CITA	CITADEL ADVISORS HOLDINGS LP		
By:	/s/ Guy Miller	By:	/s/ Noah Goldberg		
	Guy Miller, Authorized Signatory		Noah Goldberg, Authorized Signatory		
CITADEL SECURITIES GP LLC		CITA	CITADEL GP LLC		
By:	/s/ Guy Miller	By:	/s/ Noah Goldberg		
	Guy Miller, Authorized Signatory		Noah Goldberg, Authorized Signatory		
		KENI	NETH GRIFFIN		
		By:	/s/ Noah Goldberg		
			Noah Goldberg, attorney-in-fact*		

<sup>\*</sup> Noah Goldberg is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Zentalis Pharmaceuticals Inc. on April 9, 2020.